# Endogenous and environmental factors that induce DNA replication defects and genomic instability in ER-negative heterozygous BRCA1 cells

**Authors:** Madhura Deshpande, Theodore Paniza, Rebecca Brown, Kate Heslin, Nitya Patel, Advaitha Madireddy, Zev Rosenwaks, Jeannine Gerhardt

PMC · DOI: 10.1038/s41598-026-46028-5 · Scientific Reports · 2026-03-27

## TL;DR

This study shows that estrogen and the herbicide Atrazine cause DNA damage in BRCA1-mutated breast cells, but the compound I3C can help prevent this damage.

## Contribution

The study identifies environmental and endogenous factors causing DNA replication defects in ER-negative BRCA1-mutated cells and proposes I3C as a preventive agent.

## Key findings

- Estrogen and its metabolites inhibit replication fork progression and cause DNA breaks in BRCA1mut/+ cells.
- Atrazine, a common herbicide, induces genomic instability in ER-negative BRCA1mut/+ mammary cells.
- Indole-3 carbinol (I3C) reduces replication stress and genomic instability in these cells.

## Abstract

Carriers with a germline mutation in the BRCA1 gene have an increased lifetime risk of breast and ovarian cancer and other malignancies. Cancer initiation is linked to mutagenesis and loss of heterozygosity (LOH) in BRCA1 carriers. Approximately 70% of BRCA1-associated breast cancers are triple negative (TNBC; progesterone (PR), HER2, estrogen receptor (ER)-negative), which were reported to develop from ER/PR-negative luminal progenitor cells. However, the mechanisms and factors inducing carcinogenesis in ER/PR-negative cells carrying a BRCA1 germline mutation are not known. Also, ER/PR-negative breast cancer cells are not responsive to ER hormone therapy, making it challenging to treat TNBC cancers. We investigated ER-negative mammary cells and found that estrogen and estrogen metabolites, which are known to form DNA adducts, inhibit replication fork progression in heterozygous BRCA1mut/+ mammary cells. Furthermore, estrogen triggered DNA breaks, large deletions, and cancer-initiating mutations, such as LOH in BRCA1mut/+ mammary cells. In addition, we found that one of the most commonly used herbicides in the US, the endocrine-disruptor Atrazine, also hinders replication fork progression and induces genomic instability in these cells. To counteract the genotoxic effect, we tested several dietary compounds and found that Indole-3 carbinol (I3C) prevents the replication stress and reduces genomic instability in BRCA1mut/+ mammary cells. In summary, these results reveal that alterations in estrogen metabolism caused by environmental or endogenous factors are genotoxic for ER-negative BRCA1mut/+ mammary cells. And our results also show that the dietary compound I3C can prevent estrogen-induced DNA damage, and suggest that I3C can be a potential cancer-preventive therapeutic agent for BRCA1 carriers.

The online version contains supplementary material available at 10.1038/s41598-026-46028-5.

## Linked entities

- **Genes:** BRCA1 (BRCA1 DNA repair associated) [NCBI Gene 672]
- **Chemicals:** estrogen (PubChem CID 12115739), Atrazine (PubChem CID 2256), Indole-3 carbinol (PubChem CID 3712), I3C (PubChem CID 3712)
- **Diseases:** breast cancer (MONDO:0004989), ovarian cancer (MONDO:0005140), triple negative breast cancer (MONDO:0005494)

## Full-text entities

- **Genes:** POLA1 (DNA polymerase alpha 1, catalytic subunit) [NCBI Gene 5422] {aka NSX, PDR, POLA, VEODS, p180}, ESR1 (estrogen receptor 1) [NCBI Gene 2099] {aka ER, ESR, ESRA, ESTRR, Era, NR3A1}, EREG (epiregulin) [NCBI Gene 2069] {aka EPR, ER, Ep}, PGR (progesterone receptor) [NCBI Gene 5241] {aka NR3C3, PR}, CYP19A1 (cytochrome P450 family 19 subfamily A member 1) [NCBI Gene 1588] {aka ARO, ARO1, CPV1, CYAR, CYP19, CYPXIX}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, EGF (epidermal growth factor) [NCBI Gene 1950] {aka HOMG4, URG}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, POTEF (POTE ankyrin domain family member F) [NCBI Gene 728378] {aka A26C1B, POTE2alpha, POTEACTIN}, CDKN2A (cyclin dependent kinase inhibitor 2A) [NCBI Gene 1029] {aka ARF, CAI2, CDK4I, CDKN2, CMM2, INK4}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, H3P12 (H3 histone pseudogene 12) [NCBI Gene 100689229] {aka H3F3AP3, p18}, PCNA (proliferating cell nuclear antigen) [NCBI Gene 5111] {aka ATLD2}, VIM (vimentin) [NCBI Gene 7431], BRCA2 (BRCA2 DNA repair associated) [NCBI Gene 675] {aka BRCC2, BROVCA2, FACD, FAD, FAD1, FANCD}, H2AX (H2A.X variant histone) [NCBI Gene 3014] {aka H2A.X, H2A/X, H2AFX}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, TERT (telomerase reverse transcriptase) [NCBI Gene 7015] {aka CMM9, DKCA2, DKCB4, EST2, PFBMFT1, TCS1}, BRCA1 (BRCA1 DNA repair associated) [NCBI Gene 672] {aka BRCAI, BRCC1, BROVCA1, FANCS, IRIS, PNCA4}
- **Diseases:** Cancer (MESH:D009369), carcinogenic (MESH:D011230), ovarian cancer (MESH:D010051), Breast cancer (MESH:D001943), obesity (MESH:D009765), TNBC (MESH:D064726), carcinogenesis (MESH:D063646), CIN (MESH:D043171), deficient (MESH:D007153), breast and ovarian cancer (MESH:D061325), MN (MESH:D048629), toxicity (MESH:D064420), mammary gland tumors (MESH:D015674), associated (MESH:D018886)
- **Chemicals:** H2O2 (MESH:D006861), Penicillin (MESH:D010406), DMSO (MESH:D004121), methanol (MESH:D000432), Aphidicolin (MESH:D016590), CIdU (MESH:C063455), PBS (MESH:D007854), Zeranol (MESH:D015029), FA (MESH:D005557), 17beta-estradiol (MESH:D004958), Nucleotide (MESH:D009711), NaCl (MESH:D012965), 5-chloro-2'-deoxyuridine (MESH:C012244), YOYO-1 (MESH:C075296), HCl (MESH:D006851), BrdU (MESH:D001973), CO2 (MESH:D002245), Colcemid (MESH:D003703), poly-lysine (MESH:D011107), Triton X (MESH:D017830), Ethanol (MESH:D000431), dUTP (MESH:C027078), EdU (MESH:C022811), KCl (MESH:D011189), growth hormones (MESH:D013006), CEs (MESH:D002393), hydrocortisone (MESH:D006854), I3C (MESH:C016517), EGTA (MESH:D004533), Streptomycin (MESH:D013307), AP (-), agarose (MESH:D012685), ethidium bromide (MESH:D004996), WST-8 (MESH:C476329), EDTA (MESH:D004492), PIPES (MESH:C008916), Alexa Fluor 488 (MESH:C000711379), Atraz (MESH:D001280), NaOH (MESH:D012972), AZD2281 (MESH:C531550), paraformaldehyde (MESH:C003043), SDS (MESH:D012967), MgCl2 (MESH:D015636), DAPI (MESH:C007293), CCK-8 (MESH:D012844), acetic acid (MESH:D019342), F12 (MESH:C007782)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Bos taurus (bovine, species) [taxon 9913], Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** Arg to Gly change at codon 71, 185del AG
- **Cell lines:** MCF7 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0031), hTERT-IMEC — Homo sapiens (Human), Telomerase immortalized cell line (CVCL_U969), RP11 — Homo sapiens (Human), Retinitis pigmentosa, Induced pluripotent stem cell (CVCL_C904), MCF10A — Homo sapiens (Human), Spontaneously immortalized cell line (CVCL_0598)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13039430/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13039430/full.md

---
Source: https://tomesphere.com/paper/PMC13039430